Preprint Hypothesis Version 1 Preserved in Portico This version is not peer-reviewed

Encapsulated Bacteria with a Light-Repressed Deadman Switch for Liver Gene Delivery

Version 1 : Received: 24 April 2024 / Approved: 24 April 2024 / Online: 25 April 2024 (09:00:58 CEST)
Version 2 : Received: 26 April 2024 / Approved: 26 April 2024 / Online: 26 April 2024 (14:49:58 CEST)

How to cite: Renteln, M. Encapsulated Bacteria with a Light-Repressed Deadman Switch for Liver Gene Delivery. Preprints 2024, 2024041631. https://doi.org/10.20944/preprints202404.1631.v1 Renteln, M. Encapsulated Bacteria with a Light-Repressed Deadman Switch for Liver Gene Delivery. Preprints 2024, 2024041631. https://doi.org/10.20944/preprints202404.1631.v1

Abstract

Adeno-associated viruses (AAVs) have been used for liver gene therapy. Hemgenix and Roctavian are AAV-based treatments for hemophilia B and A, respectively. They cost $3 million and $2.8 million per dose, respectively. While AAV vectors may eventually be cheaper to mass produce, a bacteria-based DNA delivery system might be much cheaper for patients. Also, “bactofection” would allow for the delivery of much larger DNA packages. Such a bacterial system may now be possible, and a prototype for the liver could possibly be developed immediately.

Keywords

encapsulation; adeno-associated virus (AAV); light-activated allosteric protein switch; Deadman switch; T4 bacteriophage gene delivery vector; facultative intracellular bacteria

Subject

Biology and Life Sciences, Biology and Biotechnology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.